Drug Delivery Innovations Driving Improved Patient Compliance
NEW YORK, Aug. 9, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Drug Delivery Innovations Driving Improved Patient Compliance
http://www.reportlinker.com/p0591016/Drug-Delivery-Innovations-Driving-Improved-Patient-Compliance.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology
Introduction
This report gives in depth coverage of the factors driving patient non compliance. The report then goes on to describe and analyse key technologies being developed to improve compliance in the oral and parenteral delivery spaces. Finally the report looks at new delivery devices being developed which will improve patient compliance.
Features and benefits
* Understand the causes of poor patient compliance and the technologies that are already in use to overcome these causes.
* Assess key innovative modified release oral delivery technologies that are in development.
* Assess key innovative modified release parenteral technologies that are in development.
* Assess key innovative drug delivery devices that are in development and understand how they can improve patient compliance and for which indications.
Highlights
The importance of the oral route of administration from both a clinician and patient acceptance point of view means there has been a vast amount of development and research in drug delivery via this route. Noncompliance can be attributed to poor taste, difficulty in administration or swallowing, and the inconvenience of multiple doses per day.
Of all the modifications to parenteral delivery systems, the transdermal administration route is attracting the most attention. Across all parenteral delivery forms, the continued increase in the number of experimental protein and peptide drug candidates means that there is a high level of unmet need for delivery systems for these types of drugs.
Pharmaceutical devices will continue to drive patient compliance and acceptability as increased options make for a wider choice. The convergence of MEMS and nanotechnology with biological applications offers breakthrough in drug developments.
Your key questions answered
* What new technologies are being developed to improve patient compliance?
* Which companies are the leaders in the development of new delivery technologies aimed at improving compliance?
* What technologies in development can be applied to the specific therapy areas that my company is involved in?
* How will new technologies drive improvements in patient compliance?
* What new devices are in development that we could license to deliver our pipeline products?
Executive Summary
Overview and epidemiology of respiratory disorders
Global market analysis
Pipeline analysis
Competitive landscape
About the author
Disclaimer
Overview and epidemiology of respiratory disorders
Summary
Introduction
Asthma
Disease overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
COPD
Disease overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Allergic rhinitis
Disease overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Global market analysis
Summary
Introduction
Key events in the global respiratory market
New FDA recommendations state that LABAs cannot be used as monotherapy
FDA requires new outcomes studies for currently approved LABAs in asthma
FDA: inhalers that contain CFCs to be phased out in US
Merck's Dulera (formoterol/mometasone) approved by the FDA for asthma
Forest/Nycomed's Daxas approved in EU for severe COPD
SkyePharma's NDA for Flutiform rejected by FDA
Novartis's Xolair rejected by NICE for pediatric asthma
AstraZeneca launched Symbicort in Japan
GSK and Mitsubishi Tanabe ended Japanese tie-up for co-promotion of Adoair
Leading respiratory brands
Seretide
Singulair
Spiriva
Symbicort
Nasonex
Pulmicort
Flixotide
Combivent
Ventolin
Allegra
Market analysis by drug class
Drug class analysis
Asthma/COPD drugs
Allergic rhinitis drugs
Respiratory sales forecast to 2016
Pipeline analysis
Summary
Introduction
Key R&D events
GSK dropped darotropium from its COPD pipeline
Spiriva's safety review reveals that the drug was not associated with CV risk
Global respiratory pipeline
Leading drugs in development
Profiles of key pipeline products
Recently launched compounds
New drug application filed
Phase III compounds
Phase II compounds
Pipeline forecasts
Competitive landscape
Summary
Introduction
GSK
Merck & Co.
Boehringer Ingelheim
AstraZeneca
Novartis
Appendix
Scope
Methodology
Market size methodology
Epidemiology
Market forecast
References
Prevalence of asthma
Prevalence of COPD
Prevalence of allergic rhinitis
Abbreviations
To order this report:
Drug Delivery Technology Industry: Drug Delivery Innovations Driving Improved Patient Compliance
Drug Delivery Technology Business News
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article